Now, women with breast cancer may be able to avoid chemotherapy by taking an extra drug. The London researchers, from the Cancer Research UK Centre for Epidemiology, the Wolfson Institute for Preventive Medicine, and Queen Mary’s School of Medicine and Dentistry, combined the results of 16 other research projects into LHRH agonists and breast cancer.
LHRH agonists like the drug Zoladex switch off the ovary and stop the production of a female hormone which can encourage some tumours to grow. Many types of breast cancer are sensitive to hormones produced naturally by a woman, including the sex hormone oestrogen, and can grow faster if a woman is producing them
The overall findings offer a more reliable indicator as to how well the treatment works which is as follows:
Â¢Â Â Â Pre-menopausal women given LHRH agonists did as well as those given standard chemotherapy.
Â¢Â Â Â This is an additional, effective class of drugs in the fight against breast cancer.
Â¢Â Â Â the women did better with cancer 13% less likely to come back.